TY - JOUR
T1 - Editorial
T2 - Precision Medicine in Neurotherapeutics for Attention-Deficit/Hyperactivity Disorder
AU - Rubia, Katya
N1 - Funding Information:
Dr. Rubia has received funding from Action Medical Research (GN2426), the Garfield Weston Foundation, the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and the Maudsley NHS Foundation Trust, King's College London, and the Medical Research Council (MR/P012647/10). The funders had no involvement in the collection, analysis, and interpretation of data; the writing of the report; or the decision to submit the article for publication. Disclosure: Dr. Rubia has received funding from Takeda Pharmaceutical Co. for another project.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/7
Y1 - 2021/7
N2 - Noninvasive brain stimulation is a novel treatment avenue for attention-deficit/hyperactivity disorder (ADHD). The advantages over pharmacological treatment are relatively minimal and transient side-effects, which make it a treatment preferred by patients and parents. Neurostimulation can furthermore target key neurobiological abnormalities established over decades of neuroimaging research. Trigeminal nerve stimulation (TNS) is the only neuromodulation and device-based nonpharmacological treatment recently licensed for children with ADHD by the US Food and Drug Administration. This was based on a double-blind sham-controlled proof-of-concept trial of 4 weeks of TNS in 62 children, who showed a reduction of ADHD symptoms with an effect size of 0.5, similar to the results with second-line nonstimulant pharmacological treatment.1 Precision medicine approaches, such as establishing predictors of treatment response using relatively cost-effective cognitive and electrophysiological measures would be clinically very useful to screen children with ADHD for whom TNS is likely to be effective.
AB - Noninvasive brain stimulation is a novel treatment avenue for attention-deficit/hyperactivity disorder (ADHD). The advantages over pharmacological treatment are relatively minimal and transient side-effects, which make it a treatment preferred by patients and parents. Neurostimulation can furthermore target key neurobiological abnormalities established over decades of neuroimaging research. Trigeminal nerve stimulation (TNS) is the only neuromodulation and device-based nonpharmacological treatment recently licensed for children with ADHD by the US Food and Drug Administration. This was based on a double-blind sham-controlled proof-of-concept trial of 4 weeks of TNS in 62 children, who showed a reduction of ADHD symptoms with an effect size of 0.5, similar to the results with second-line nonstimulant pharmacological treatment.1 Precision medicine approaches, such as establishing predictors of treatment response using relatively cost-effective cognitive and electrophysiological measures would be clinically very useful to screen children with ADHD for whom TNS is likely to be effective.
UR - http://www.scopus.com/inward/record.url?scp=85102727615&partnerID=8YFLogxK
U2 - 10.1016/j.jaac.2020.11.013
DO - 10.1016/j.jaac.2020.11.013
M3 - Editorial
C2 - 33264662
AN - SCOPUS:85102727615
SN - 0890-8567
VL - 60
SP - 813
EP - 815
JO - Journal of the American Academy of Child and Adolescent Psychiatry
JF - Journal of the American Academy of Child and Adolescent Psychiatry
IS - 7
ER -
